Beijing Leadman Biochemistry Co.,Ltd. Stock price

Equities

300289

CNE100001C22

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
4.73 CNY +0.85% Intraday chart for Beijing Leadman Biochemistry Co.,Ltd. -5.96% -23.09%
Sales 2022 706M 97.75M Sales 2023 462M 63.91M Capitalization 3.35B 463M
Net income 2022 -56M -7.75M Net income 2023 15M 2.08M EV / Sales 2022 3.32 x
Net cash position 2022 787M 109M Net cash position 2023 846M 117M EV / Sales 2023 5.41 x
P/E ratio 2022
-57.6 x
P/E ratio 2023
205 x
Employees 519
Yield 2022 *
-
Yield 2023
-
Free-Float 17.65%
More Fundamentals * Assessed data
Dynamic Chart
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Leadman Biochemistry Unit Obtains Shanghai Clearance for Fatty Acid Kit MT
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Shenzhen Uni-medica Technology Co., Ltd. announced that it has received CNY 20 million in funding from Beijing Leadman Biochemistry Co.,Ltd. CI
Shenzhen Uni-medica Technology Co., Ltd. announced that it expects to receive CNY 20 million in funding from Beijing Leadman Biochemistry Co.,Ltd. CI
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Beijing Leadman Biochemistry Co.,Ltd. Approves Cash Dividend for the Year 2021 CI
Beijing Leadman Biochemistry Co.,Ltd. Proposes Final Dividend for the Year 2021 CI
Beijing Leadman Biochemistry Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Beijing Leadman Biochemistry Co.,Ltd. Approves Board Appointments CI
More news
1 day+0.85%
1 week-5.96%
Current month+5.11%
1 month+8.24%
3 months-21.82%
6 months-20.77%
Current year-23.09%
More quotes
1 week
4.59
Extreme 4.59
4.95
1 month
4.43
Extreme 4.43
5.08
Current year
3.45
Extreme 3.45
6.38
1 year
3.45
Extreme 3.45
6.74
3 years
3.45
Extreme 3.45
9.69
5 years
3.45
Extreme 3.45
9.87
10 years
3.45
Extreme 3.45
30.90
More quotes
Managers TitleAgeSince
Director of Finance/CFO 40 19-05-31
Investor Relations Contact - -
Corporate Secretary 45 16-10-31
Members of the board TitleAgeSince
Corporate Officer/Principal 49 -
Chairman - 20-08-27
Director/Board Member 49 21-11-29
More insiders
Date Price Change Volume
24-03-28 4.73 +0.85% 7,539,091
24-03-27 4.69 -1.68% 6,331,282
24-03-26 4.77 -0.83% 5,587,800
24-03-25 4.81 -1.84% 4,994,000
24-03-22 4.9 -2.58% 5,317,100

End-of-day quote Shenzhen S.E., March 27, 2024

More quotes
Beijing Leadman Biochemistry Co., Ltd is a China-based company principally engaged in the research, development, production and sales of in-vitro diagnostic reagents. Its diagnostic reagents include chemiluminescence diagnostic reagents and biochemical diagnostic agents, such as hepatitis B virus attributes and tumor markers. The Company also produces diagnostic instruments and biochemical raw materials. Its diagnostic instruments include automatic luminescence immunity analyzers, among others. Its products are applied in various fields, including liver diseases, kidney diseases, cardiovascular diseases, immunological diseases and diabetes, among others. The Company mainly operates businesses in domestic market.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Beijing Leadman Biochemistry Co.,Ltd. - Shenzhen S.E.